AwesomeCapital

Anika Therapeutics EPS beats by $0.27, beats on revenue

Anika Therapeutics (NASDAQ:ANIK): Q2 GAAP EPS of $0.67 beats by $0.27.

Revenue of $30.42M (-0.4% Y/Y) beats by $3.01M.

Shares -0.07%.

Press Release

https://seekingalpha.com/news/3481107-anika-therapeutics-eps-beats-0_27-beats-revenue

Varian Medical Systems EPS beats by $0.19, beats on revenue

Varian Medical Systems (NYSE:VAR): Q3 Non-GAAP EPS of $1.32 beats by $0.19; GAAP EPS of $0.32 misses by $0.70.

Revenue of $825.8M (+16.5% Y/Y) beats by $63.51M.

Press Release

https://seekingalpha.com/news/3481119-varian-medical-systems-eps-beats-0_19-beats-revenue

LeMaitre Vascular EPS beats by $0.02, beats on revenue

LeMaitre Vascular (NASDAQ:LMAT): Q2 GAAP EPS of $0.23 beats by $0.02.

Revenue of $29.48M (+9.1% Y/Y) beats by $0.58M.

Press Release

https://seekingalpha.com/news/3481123-lemaitre-vascular-eps-beats-0_02-beats-revenue

Cerner reports mixed Q2, outlook

Cerner (NASDAQ:CERN) -0.1% reports mixed Q2 results that beat EPS estimates but missed on revenue. The Q3 outlook has in-line revenue of $1.405-1.455B (consensus: $1.43B) and downside EPS of $0.65-0.67 (consensus: $0.68).

The reiterated in-line FY19 view has revenue of $5.65-5.85B (consensus: $5.74B) and EPS of $2.64-2.72 (consensus: $2.67).

Q2 bookings came in at the higher end of the company’s guidance at $1.43B.

The operating cash flow totaled $206.8M and the FCF was a negative $22.2M.

Press release.

Earnings call starts at 4:30 PM ET with a webcast here.

https://seekingalpha.com/news/3481141-cerner-reports-mixed-q2-outlook

Bristol Opdivo + Yervoy combo results mixed in first-line lung cancer study

Results from Part 1a of the Phase 3 CheckMate-227 study evaluating Bristol-Myers Squibb’s (NYSE:BMY) combo therapy of Opdivo (nivolumab) + low-dose Yervoy (ipilimumab) versus chemo in first-line PD-L1-positive (at least 1%) non-small cell lung cancer (NSCLC) met the co-primary endpoint of a statistically significantly improvement in overall survival (OS) compared to chemo.

No new safety signals were observed.

Part 2 of CheckMate-227 failed to demonstrate a statistically valid effect on OS versus chemo in non-squamous NSCLC patients.

Complete results will be submitted for presentation at a future medical conference.

Shares are down 4% after hours.

https://seekingalpha.com/news/3481228-bristol-myers-opdivo-yervoy-combo-shows-mixed-results-first-line-lung-cancer-study-shares-4